Celgene (NASDAQ: CELG): Triple Threat To Revlimid Becomes More Tangible - BMO
Tweet Send to a Friend
BMO Capital analyst, M. Ian Somaiya reiterated his Outperform rating on shares of Celgene (NASDAQ: CELG) after Genmab/JNJ’s daratumumab achieved ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
